Share the post "DII Data:Stock Market Insights on 20 Sep -Concord Biotech"
Company Logo | Company | Client Name | Buy/Sell | Qty Traded | Price | Trader Name |
---|---|---|---|---|---|---|
One Global Service Provider | Nexpact | Buy | 50K | 141.10 | Na | |
Concord Biotech | Ubs Principal Capital Asia | Sell | 740K | 2589.86 | The Vanguard Group Inc A/c Vanguard Total International Stock Index Fund | |
Marksans Pharma | Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard International Equity Index Funds | Buy | 2M | 316.85 | Graviton Research Capital Llp | |
Vanguard Total International Stock Index Fund | Buy | 2M | 316.85 | Graviton Research Capital Llp |
The 50K shares of One Global Service Provider have been purchased by the by Nexpact through Domestic Investments at a price of ₹141.10 per share.
The 740K shares of Concord Biotech have been sold by the by Ubs Principal Capital Asia through Domestic Investments at a price of ₹2589.86 per shareand it is purchased by The Vanguard Group Inc A/c Vanguard Total International Stock Index Fund at a price of ₹2589.86 per share.
The 2M shares of Marksans Pharma have been purchased by the by Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard International Equity Index Funds through Domestic Investments at a price of ₹316.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹316.85 per share.
The 2M shares of Marksans Pharma have been purchased by the by Vanguard Total International Stock Index Fund through Domestic Investments at a price of ₹316.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹316.85 per share.
ONE GLOBAL SERVICE PROVIDER LIMITED
0.00
Net Sales
17.58
Net Profit
135.60
Total Income
-112.13
Expenditure
134
Current Price
95.1
Market Cap
For ONE GLOBAL SERVICE PROVIDER LIMITED, the latest financial data showcases impressive results. The company reported net sales of ₹0.00 million and total income of ₹135.60 million for the quarter. Expenditure was ₹-112.13 million, resulting in a net profit of ₹17.58 million. EPS for continuing operations was ₹2.47. Additional financial details include other income of ₹0.00 million, finance costs of ₹0.00 million, and employee benefit expenses of ₹-3.02 million. Depreciation and amortization expenses were ₹-0.43 million. Current tax was ₹-5.91 million and deferred tax amounted to ₹0.02 million. Total comprehensive income for the period was ₹0.00 million, with other comprehensive income net of taxes at ₹0.00 million.
Valued at ₹95.1 crore, the company's stock trades at ₹134, with historical highs and lows of ₹155 / 29.2. The P/E ratio of 13.4 reflects a high stock valuation. The book value is ₹20.3, and the dividend yield is 0.00%. ROCE is at 84.9%, and ROE is 65.6%. The company’s minimal debt-to-equity ratio of 0.02 contrasts with its negative net cash flow of ₹1.20 crore. The Piotroski score is 7.00, and the Graham Number of ₹67.6 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 6.61 indicates a premium valuation.
Concord Biotech Limited
2,158.02
Net Sales
595.93
Net Profit
2,261.09
Total Income
1,479.42
Expenditure
2,225
Current Price
23,274
Market Cap
In Concord Biotech Limited's recent financial report, the data highlights a robust performance. Net sales reached ₹2,158.02 million, with total income of ₹2,261.09 million. The expenditure was ₹1,479.42 million, leading to a net profit of ₹595.93 million. Earnings per Share (EPS) for continuing operations were reported at ₹5.70. The financial overview also includes other income of ₹103.08 million, finance costs of ₹2.41 million, and employee benefit expenses totaling ₹316.64 million. Depreciation and amortization expenses were ₹131.79 million. Current and deferred taxes were recorded at ₹193.94 million and ₹5.34 million, respectively. The total comprehensive income for the period was ₹597.62 million, and other comprehensive income net of taxes was ₹1.69 million.
The company has a market capitalization of ₹23,274 crore and a current stock price of ₹2,225. Historically, the stock has fluctuated between ₹2,664 / 992. With a Price-to-Earnings (P/E) ratio of 74.3, the stock appears highly valued. The book value per share is ₹146, and the dividend yield is 0.39%. The Return on Capital Employed (ROCE) is 28.1% and the Return on Equity (ROE) is 21.1%. The debt-to-equity ratio is very low at 0.01, although the company reports a net cash flow of ₹11.6 crore. The Piotroski score is 8.00, and the Graham Number estimates the intrinsic value of the stock at ₹314. The Price-to-Book (P/B) ratio is 15.2, indicating the stock is trading at a premium relative to its book value.
Marksans Pharma Limited
2,545.27
Net Sales
320.15
Net Profit
2,626.79
Total Income
2,203.80
Expenditure
240
Current Price
10,876
Market Cap
In the most recent financial analysis for Marksans Pharma Limited, key metrics demonstrate a solid performance. The net sales reached ₹2,545.27 million, with total income amounting to ₹2,626.79 million. Expenditure was recorded at ₹2,203.80 million, resulting in a net profit of ₹320.15 million. EPS figures for continuing operations are ₹0.71. Other notable figures include other income of ₹81.52 million, finance costs of ₹2.83 million, and employee benefit expenses totaling ₹231.93 million. Depreciation and amortization expenses were ₹68.36 million, with current tax at ₹103.58 million and deferred tax at ₹-0.74 million. The total comprehensive income for the period was ₹320.86 million, and other comprehensive income net of taxes was ₹0.71 million.
Valued at ₹10,876 crore, the company's stock trades at ₹240, with historical highs and lows of ₹243 / 93.8. The P/E ratio of 32.7 reflects a high stock valuation. The book value is ₹45.6, and the dividend yield is 0.25%. ROCE is at 20.6%, and ROE is 16.5%. The company’s minimal debt-to-equity ratio of 0.12 contrasts with its negative net cash flow of ₹20.8 crore. The Piotroski score is 4.00, and the Graham Number of ₹86.9 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 5.27 indicates a premium valuation.